Nonnucleoside Reverse Transcriptase Inhibitor
University of Paris publishes research in nonnucleoside reverse transcriptase inhibitor
Published in AIDS Weekly, February 15th, 2010
"To identify factors associated with virological response (VR) to an etravirine (ETR)-based regimen, 243 patients previously treated with nonnucleoside reverse transcriptase inhibitors (NNRTIs) were studied. The impact of baseline HIV-1 RNA, CD4 cell count, past NNRTIs used, 57 NNRTI resistance mutations, genotypic sensitivity score (GSS) for nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), and the number of new drugs used with ETR for the first time on the VR to an ETR regimen were investigated," researchers in Paris, France report.
"Among the 243 patients, the median baseline HIV-1 RNA level was 4.4 log(10) copies/ml (interquartile...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2010-02-15)
More Articles from AIDS Weekly
- Dartmouth College
New vaccine effective in preventing TB in African patients with HIV infection - Imperial College London
HIV researchers solve key puzzle after 20 years of trying - Springer
Call for AIDS denialists to be held accountable - Anemia
Report summarizes anemia study findings from T. Ferry and co-researchers - Antifungals
Researchers from China Agricultural University detail findings in antifungals - Antiretroviral
Researchers from University Hospital report recent findings in antiretroviral - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
